Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Cancer-associated fibroblasts (CAFs) play a role in response to cancer treatment and
patient prognosis. CAFs show phenotypic and functional heterogeneity and differ widely in …

The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the
most prevalent cancers worldwide. While the clinical approach to BCa has remained largely …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …